Main Article Content

Authors

Acute glomerulonephritis (GNA) is a wide group of diseases with the common characteristics of abrupt onset and proliferation of endocapillary glomerular cells. Clinically, they usually manifest as acute nephritic syndrome: hematuria, acute renal failure, hypertension and mild proteinuria, although they can appear as recurrent hematuria. GNA can be present in association with a variety of bacterial and viral infections, but in most cases the initial antigenic initiating stimulus is unknown. Patients with rapidly progressive glomerulonephritis often present acute onset of manifestations of nephritis, such as azotemia, oliguria, edema, hypertension, proteinuria, and hematuria with «active» urine sediment that often contains red blood cell casts, pigmented casts, and cellular debris. This article, aimed at all primary care staff and seeking to increase their awareness of this disease, discusses in more detail the clinical, pathogenesis, pathology, and treatments available from one of the glomerulonephritis with greater impact on survival patient.

Levy JeB, Pasey CD. Crescentic glomerulonephritis. En:Brady HR, Wilcox CS. (Eds.). Therapy in nephrology andhipertensión. 2a ed. Philadelphia: Saunders; 2003. p. 177-88.2.Chadban SJ, Atkins RC. Glomerulonephritis. Lancet. 2005;365: 1797-806.3.Glassock RJ. Hematuria and pigmenturia. En: Massry SG.Glassock RJ (Eds.). Textbook of nephrology. 4th ed.Philadelphia: Lippincott Williams & Wilkins; 2001. p. 503-12.4.Shirier RW (Ed). Diseases of the kidney and urinary tract. 8aed. Philadelphia: Lippincott, Williams and Wilkins; 2007.5.Kiperova B. The treatment of glomerular disease a compromisebetween the standard and the individual approach. NDT.2003; Supl 5: 31-3.6.Lau KK, Wyatt RJ. Glomerulonephritis. Adolesc Med. 2005;16: 67-85.7.Ballinger S. Henoch Schonlein purpura. Curr Opin Rheumatol.2003; 15:591-4.8.Ponticelli C, Fogazzi GB. Primary glomerular diseases. En:Malluche HH, Sawaya BP, Hakim RM, Sayegh MH (Eds.).Clinical nephrology, dialysis and transplantation. Cap 6. 4aed. 2009. p. 1-58.9.Reza Ardalan M, Mohajel Shoja M. Rapidly progressiveglomerulonephritis in a patient with brucelosis. Nephrol DialTransplant. 2006; 21: 1743-4.10. Masani NN, Imbriano LJ, D’Agati VD, Markowitz S. SLE andrapidly progressive glomerulonephritis. Am J Kidney Dis.2005; 45: 950-5.11. Langforda CA. Balow JE. New insights into the immunopatho-genesis and treatment of small vessel vasculitis of the kidney.Curr Opin Nephrol Hypertens. 2003; 12: 267-72.12. Marinaki S, Kalsch AI, Grimminger P, Breedijk A, Birck R,Schmitt WH, et al. Persistent T-cell activation and clinicalcorrelations in patients with ANCA-associated systemicvasculitis. Nephrol Dial Transplant. 2006; 21: 1825-32.13. Braun-Moscovici Y, Furst DE. Immunoglobulin for rheumaticdiseases in the twenty-first century: ¿take it or leave it? CurrOp Rheumatol. 2003; 15: 237-45.14. Winters JL, Pineda AAG. New directions in plasma exchange.Curr Op Hematol. 2003; 10: 424-8.15. Di Marco V, De Lisi1S, Li Vecchi M. Therapy with lamivudineand steroids in a patient with acute hepatitis B and rapidlyprogressive glomerulonephritis. Kidney Internat. 2006; 70:1187-8.16. Falk RJ, Hoffman GS. Controversies in small vessel vasculitiscomparing the rheumatology and nephrology view. Curr OpRheumatol. 2007; 19: 1-9.17. Department of Health and Human Services. Food and DrugAdministration. Blood vessels recovered with organs andintended for use in organ transplantation. Federal Register.2007; 72: 10922-5.18. Walters GD, Willis NS, Craig JC. Interventions for renalvasculitis in adults. A systematic review. BMC Nephrol. 2010;11: 12.

Colombia MédicaVol. 42 Nº 4, 2011 (Octubre-Diciembre)19. Jennette JC. Rapidly progressive crescentic glomerulonephritis.Kidney Internat. 2003; 63: 1164-77.20. Ramos R, Soto C. Es necesaria la implantación de la consultanefrológica extrahospitalaria. Nefrologia. 2006; 26: 401-2.21. Nair R, Bell JM, Walker PD. Renal biopsy in patients aged 80years and older. Am J Kidney Dis. 2004; 44: 618-26.22. Jamal S, Wakeel A, Mitwalli AH, Tarif N, Alam AA, et al.Spectrum and outcome of primary glomerunephritis. Saudi JKidney Dis Transplant. 2004; 15: 440-6.23. Sahin GM, Sahin S, Kantarci G, Ergin H. Mycophenolatemofetil treatment for therapy-resistant glomerulopathies.Nephrology. 2007; 12: 285-8.24. Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, etal. Histopathologic classification of ANCA-AssociatedGlomerulonephritis. J Am Soc Nephrol. 2010; 21: 1628-36.25. Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P,Kitching AR, et al. Molecular architecture of the goodpastureautoantigen in anti-GBM nephritis. N Engl J Med. 2010; 363:343-54 DOI: https://doi.org/10.1056/NEJMoa0910500

Castro, A. L., Huertas, J. F., & Hurtado, J. S. (2024). Acute glomerulonephritis, rapidly progressive emphasis on commitment. Colombia Medica, 42(4), 536–548. https://doi.org/10.25100/cm.v42i4.956 (Original work published November 24, 2011)

Downloads

Download data is not yet available.